The multiple sclerosis drug dalfampridine (Ampyra) can cause seizures in patients who are starting the medicine at normal doses, the FDA warned Monday.
Postmarketing adverse event reporting indicated that most seizures happened in patients with no history of seizures and occurred within days or weeks of starting the drug at its recommended dosage.
